Effects of statins on biomarkers of bone metabolism: A randomised trial

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 11, Issue 2, 2001, Pages 84-87

  Stein, E A ^a   Farnier, M ^b   Waldstreicher, J ^c   Mercuri, M ^c  

^a Pharmaceutical Product Development   (United States)

^b Point Medical   (France)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Bone metabolism; Simvastatin

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PEPTIDE; PYRROLE DERIVATIVE; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD; BONE; BONE DEVELOPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALKALINE PHOSPHATASE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DEVELOPMENT; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PEPTIDES; PYRROLES; SIMVASTATIN;

EID: 0035319125     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Reld IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N, on behalf of the LIPID Study Group (2001) Effect of pravastatin on frequency of fracture in the LIPID Study: Secondary analysis of a randomized trial. Lancet 357: 509-512
2. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc 283: 3205-3210
3. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. J Am Med Assoc 283: 3211-3216
4. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355: 2185-2188
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation by in vitro and in rodents by statins. Science 286: 1946-1949
6. Cummings SR, Bauer DC (2000) Do statins prevent both cardiovascular disease and fracture? JAMA 283: 3255-3257
7. Crouse III JR, Frohlich J, Ose L, Mercuri M, Tobert JA (1999) Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 83: 1476-1477
8. Dawson-Hughes B, Harris SS, Krall EA, Dallal FE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670-676
9. Downs Jr RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME (2000) Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85: 1783-1788
10. Black Dm, Cummings SR, Karpf DB, et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541
11. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 280: 2077-2082
12. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9: 461-468
13. Lanza FL, Schwartz H, Sahba S, Malaty HM, Musliner TA, Reyes R, Quan H, Graham DY (2000) An endoscopic comparison of effects of alendronate and resedronate on upper gastrointestinal mucosae. Am J Gastroenterol 95: 3112-3117
14. Furberg CD (1999) Natural statins and stroke risk. Circulation 99: 185-188
15. MRC/BHF Heart Protection Study Collaborative Group (1999) MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20: 725-741
16. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus JTM, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L (1996) Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156: 2085-2092